Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas

Trial Profile

Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2013

At a glance

  • Drugs Alisertib (Primary)
  • Indications Bladder cancer; Lymphoma; Mesothelioma; Ovarian cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Millennium; Takeda
  • Most Recent Events

    • 23 Oct 2013 Results for part A presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top